The anti-apoptotic genes Bcl-XLand Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+cells-Reference-Cited by-同舟云学术

The anti-apoptotic genes Bcl-XLand Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+cells

Published:2002-07-25 Issue:2 Volume:118 Page:521-534
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Konopleva Marina,Zhao Shourong,Hu Wei,Jiang Shuwei,Snell Virginia,Weidner Douglas,Jackson C. Ellen,Zhang Xin,Champlin Richard,Estey Elihu,Reed John C.,Andreeff Michael

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2002.03637.x/fullpdf

Reference53 articles.

1. The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems;Abramson;Journal of Experimental Medicine,1997

2. The Bcl-2 protein family: arbiters of cell survival;Adams;Science,1998

3. Prognostic value of DNA/RNA flow cytometry in myeloblastic and lymphoblastic leukemia in adults: RNA content and S-phase predict remission duration and survival in multi-variate analysis;Andreeff;Annals of the New York Academy of Science,1986

4. Expression of bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid;Andreeff;Leukemia,1999

5. Fas-induced activation of the cell death-related protease CPP32 Is inhibited by Bcl-2 and by ICE family protease inhibitors;Armstrong;Journal of Biological Chemistry,1996

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer stem cells: advances in knowledge and implications for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-05

2. Overview: Cancer Stem Cells;Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays;2024

3. Refractory/Relapsed AML in Children and Evolution of Novel Therapies;Pediatric Oncology;2024

4. Nanomedicine Based Therapies Against Cancer Stem Cells;Recent Progress in Pharmaceutical Nanobiotechnology: A Medical Perspective;2023-12-27

5. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial;Frontiers in Immunology;2023-11-20